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Abstract
Therapy-induced senescence (TIS), a cytostatic stress response in cancer cells, is induced inefficiently by current
anticancer agents and radiation. The mechanisms that mediate TIS in cancer cells are not well defined. Herein, we
characterize a robust senescence response both in vitro and in vivo to the quinone diaziquone (AZQ), previously iden-
tified in a high-throughput senescence-induction small-molecule screen. Using AZQ and several other agents that
induce senescence, we screened a series of cyclin-dependent kinase inhibitors and found that p27Kip1 was induced
in all investigated prostate cancer cell lines. The ubiquitin-ligase Skp2 negatively regulates p27Kip1 and, during TIS, is
translocated to the cytoplasm before its expression is decreased in senescent cells. Overexpression of Skp2 blocks
the effects of AZQ on senescence and p27Kip1 induction. We also find that stable long-term short hairpin RNA knock-
down of Skp2 decreases proliferation but does not generate the complete senescence phenotype. We conclude that
Skp2 participates in regulating TIS but, alone, is insufficient to induce senescence in cancer cells.
Translational Oncology (2012) 5, 278–287
Introduction
Accelerated or induced senescence is a regulated cellular response to
sublethal stress wherein cells develop a permanently growth-arrested
phenotype with distinct morphologic and biochemical characteristics
[1–3]. These features include development of a flattened and enlarged
morphology in vitro and increased senescence-associated β-galactosidase
(SA-β-gal) activity in both cells and tissues [4]. Other characteristics
of senescence have been used as surrogate markers including DNA
damage and damage response signaling activities [5–7], secreted signal-
ing factors [8], and other marker genes including Maspin and Cspg2
[9,10]. Increased expression of one or more cyclin-dependent kinase
inhibitor (CDKI) proteins, including p16Ink4a and p21Waf1/Cip1, is criti-
cal to senescence [11]. In fibroblast-derived cell lines, transient expres-
sion of p16Ink4a or p21Waf1/Cip1 induces senescence [7,12]. Deregulated
CDKI expression contributes to senescence bypass and oncogenic
transformation [3,11]. As the regulation of many of these pathways is
affected in cancer, the contribution of CDKI protein regulation to
therapy-induced senescence (TIS) of cancer cells remains undefined.
TIS occurs in tumors in response to radiotherapy or selected chemo-
therapy agents and is a potential strategy for cancer treatment [13,14].
Subtoxic doses of DNA damaging drugs induce senescence in cancer
cells in vitro, including cells lacking p53 and other tumor suppressors
[9,15,16]. Importantly, senescence has been observed, albeit infre-
quently, in patient tumors removed after treatment with genotoxic
anticancer agents [17,18]. In cancer cells, senescence seems to have a
neutral or antiproliferative effect on surrounding bystander cells
[19,20]. In vivo, senescence induced genetically in tumor models results
in immune-related tumor regression and extended survival [21,22]. Re-
cently, senescence in colorectal cancer patients correlated with longer
tumor-free survival after 5-fluorouracil/leucovorin treatment [23]. In
all, accumulating evidence suggests that senescence in tumor tissues
may prove to be a beneficial response to therapy.
TIS has not been widely studied in tumor models owing to a lack
of effective compounds specifically inducing this phenotype. We re-
cently identified diaziquone (AZQ) in a high-throughput screen for
senescence-inducing drugs [24]. This compound is a rationally de-
signed DNA-alkylating compound previously developed as an anti-
cancer agent [25]. These early investigations focused on the extent
that AZQ induced tumor cell death and did not take into account
the possibility of tumor cell senescence as a response to treatment.
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Skp2 and p27Kip1 mediate the development of prostate intra-
epithelial neoplasia and characteristics of the senescent phenotype
[26]. The E3-ubiquitin ligase Skp2 is central to the control of a number
of important cancer-related processes. Skp2 is an F-box protein that
regulates the specificity of ubiquitin-conjugating protein complexes,
resulting in ubiquitination and subsequent degradation of a repertoire
of targeted proteins [27]. Skp2 negatively regulates the expression of the
CDKI p27Kip1, with increased Skp2 expression decreasing p27Kip1 and
resulting in proliferation. In prostate and other cancers, elevated Skp2
expression predicts poor prognosis [28,29] and is regulated by path-
ways affecting prostate carcinogenesis, including androgen receptor
signaling [30] and the phosphoinositide 3-kinase/PTEN/Akt pathway
[31–33]. Skp2 expression is also regulated by other pathways, includ-
ing Cks1, anaphase-promoting complex/cyclosome, and the Forkhead-
related transcription factor FOXM1 [27,34,35]. Although this body of
evidence demonstrates the importance of Skp2 and p27Kip1 in regulat-
ing proliferation, the role of these proteins in TIS of cancer cells has not
been addressed.
In the current study, we characterize senescence induction using
AZQ and other compounds to investigate a novel role for Skp2 and
p27Kip1 in the regulation of TIS. We find that while Skp2 is required
for the induction of TIS, its down-regulation alone is insufficient to
induce senescence.
Materials and Methods
Cell Lines and Reagents
DU145, PC3, and LNCaP cells were cultured as previously de-
scribed [16,20]. AZQ (NSC 182986) was provided by the Develop-
mental Therapeutics Program, Division of Cancer Treatment and
Diagnosis, National Cancer Institute, National Institutes of Health
(Bethesda, MD). Chemical information was obtained from PubChem
(www.ncbi.nlm.nih.gov/sites/entrez). Doxorubicin and 5-azacytidine
(5-AZA) were purchased from Sigma (St Louis, MO).
Viable Cell Counting, Side Scatter, and Cell Cycle Modeling
DU145 and PC3 cells were plated in six-well plates at a density of
50,000 cells per well and LNCaP cells plated at a density of 200,000
cells per well. After overnight incubation, cells in sample wells were col-
lected and stained with Annexin V–Alexa 488 and propidium iodide
(PI; Invitrogen, Carlsbad, CA). The fraction and number of viable cells
in each sample was measured by flow cytometry and calculated as pre-
viously described [20]. Simultaneously, the cellular granularity of viable
cells in each sample was measured as side scatter (SSC). Parallel samples
were then cultured for 3 days in medium containing 250 nM AZQ
before counting or were cultured in 250 nM AZQ for 3 days followed
by washing in phosphate-buffered saline (PBS) and three additional
days of culture in drug-free medium before they were collected and
counted. Flow cytometry data were analyzed using WinMDI (Joseph
Trotter, Scripps Research Institute, La Jolla, CA). In addition, parallel
samples cultured and treated on glass cover slips were fixed and stained
for SA-β-gal activity as previously described [4] and visualized by light
microscopy. For cell cycle modeling, cells were collected and stained
using PI, and cellular DNA content was measured by flow cytometry
as previously described [20,36]. The cell cycle phase was estimated
using Cylchred by Terry Hoy of University of Wales College of
Medicine (Cardiff, United Kingdom).
DU145 Xenograft Tumors
Animal protocols and studies were performed in accordance with
the guidelines of the Association for the Assessment and Accreditation
of Laboratory Animal Care International, and approval was obtained
from the University of Wisconsin Institutional Animal Care and Use
Committee. Male athymic nude mice were purchased from Harlan
(Madison, WI), and xenograft tumors were established and measured
as previously described [20,37]. When tumors reached measurable size
(1 mm3), mice were given intraperitoneal injections of PBS or 4 mg of
AZQ per kilogram body weight three times a week for 3 weeks. This
dosage is approximately half the reported maximum tolerable dose in
mice [25]. Tumor size was monitored until exceeding 1200 mm3, at
which time tumors were harvested; tumors that had not exceeded this
size were harvested 15 weeks after tumors were initially detected. Tumor
samples were frozen in a sectioningmedium or fixed in paraformaldehyde
and embedded in paraffin. Sections of frozen tumors were stained for
SA-β-gal activity as previously described [4]. AdditionalDU145 xenograft
tumors were administered single doses of PBS or AZQ, harvested 7 days
later, and frozen or fixed and embedded, as mentioned previously.
Immunohistochemistry
Collected tissues were fixed for 24 hours in 10% neutral buffered
formalin, dehydrated, paraffin infiltrated, and paraffin embedded. Tissue
sections were cut at 5 μm and mounted on slides. Sections were
deparaffinized in xylene, hydrated through graded ethyl alcohols to
water, washed with PBS, subjected to antigen retrieval, and blocked with
10% goat serum in PBS. Endogenous peroxidase was blocked with 0.3%
hydrogen peroxide in methanol. Endogenous biotin was blocked with
0.001% avidin in PBS and quenched with 0.001% biotin in PBS. Sec-
tions were then incubated with primary antibody at a 1:25 dilution in
PBS with 1% goat serum overnight at 4°C, washed with PBS, and in-
cubated with biotinylated goat anti-rabbit or antimouse secondary anti-
bodies (Vector Laboratories, Burlingame, CA) at 1:200 in PBS at room
temperature. Slides were washed in PBS, incubated at room temperature
with Vectastain ABC Elite (Vector Laboratories), washed in PBS, devel-
oped with diaminobenzidine (Vector Laboratories), and counterstained
with Mayer hematoxylin. Stained sections were visualized by light
microscopy. Primary antibodies: p27Kip1 (no. 610242; BD Biosciences,
Lexington, KY), Ki-67 (VP-K452; Vector Laboratories, Inc), and cleaved
caspase 3 (no. 9661; Cell Signaling Technology, Beverly, MA).
Cell Lysates and Protein Immunoblot Analysis
DU145, PC3, and LNCaP cells were cultured in growth medium or
medium containing 250 nM AZQ for 3 days, and cells were exposed to
AZQ followed by 3 days in drug-free medium, washed with warm PBS,
scraped from culture plates, collected, pelleted, and solubilized in lysis
buffer (PBS containing 2% NP-40, 10 mM NaF, 1 mM Na4VO3,
10 μg/ml aprotinin, 10 μg/ml leupeptin), removing insoluble debris by
centrifugation. Equal amounts of total cell protein in each lysate were sepa-
rated by SDS-PAGE in 4% to 12% Bis/Tris gradient gels (Invitrogen)
and transferred to nitrocellulose membranes. Membranes were blocked
and probed with antibodies, as previously described [36,38].
In additional experiments, DU145 and PC3 cells were cultured in
250 nM AZQ (as above), 25 nM doxorubicin, or 400 nM 5-AZA, as
previously described [16]. Cells were solubilized in lysis buffer after 2
and 3 days in medium containing each respective drug or after 3 days in
drug-containing medium plus 3 days of culture in drug-free medium.
Antibodies were as follows: p15Ink4b (sc-613), p16Ink4a (sc-468),
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p21Waf1/Cip1 (sc-397), p27Kip1 (sc-528), p57Kip2 (sc-1040), and Skp2
(sc-7164; Santa Cruz Biotechnology, Santa Cruz, CA); α-tubulin
(CP06; Calbiochem, San Diego, CA); HRP-conjugated anti-mouse
and anti-rabbit secondary antibodies (nos. 31432 and 31464; Thermo/
Pierce, Rockford, IL). Band intensities were measured using ImageJ
(http://rsbweb.nih.gov/ij/), background intensities were subtracted and
normalized to α-tubulin intensities and expressed in relative units as
a function of control band intensity. In each case, the immunoblot
presented is representative of at least three experiments.
Immunofluorescence of p27Kip1 and Skp2
PC3 cells were plated on glass cover slips. Control proliferating
cells or cells treated with 250 nM AZQ for 2, 3, or 3 days plus three
additional days in drug-free medium were fixed in paraformaldehyde
and stained as previously described [33] using antibodies recognizing
p27Kip1 (BD Biosciences) and Skp2 (Santa Cruz), with Alexa 488 or
Alexa 594–conjugated secondary antibodies (Invitrogen). Nuclei were
stained using Hoechst 33342 (Invitrogen). Cells and tissues were visu-
alized using fluorescence microscopy as previously described [20,39].
Skp2 Expression and Effects on Proliferation
The complementary DNA (cDNA) for Skp2 was purchased from
Open BioSystems (no. IHS1380-97652024; Huntsville, AL) and sub-
cloned into the pCDNA3.1(+) expression vector (Invitrogen) where the
cDNA sequence was confirmed. Equal amounts of Skp2-pCDNA3.1
and pSico-PGK-GFP (Addgene, Cambridge, MA) were coelectro-
porated into DU145 and PC3 cells using the Amaxa Nucleofector
System and reagents (Lonza, Basel, Switzerland). Control samples were
transfected with a pCDNA3.1 vector containing the LacZ cDNA. After
electroporation, cells were incubated overnight in growth medium, and
medium was replaced with drug-free medium or medium containing
250 nM AZQ and cultured for two additional days. Samples were sol-
ubilized in lysis buffer, and expressions of Skp2, p27Kip1, and α-tubulin
were assessed by immunoblot analysis, as mentioned previously. In
parallel samples, nonfixed cells were collected and suspended in PBS
containing both 50 μg/ml PI (to identify viable cells) and 10 μg/ml
Hoechst 33342 (to assess DNA content), as previously described [40].
Samples were analyzed by flow cytometry using an LSR-II flow cytom-
eter (Becton-Dickinson, Franklin Lakes, NJ) to measure DNA content
in viable, green fluorescent protein (GFP)–coexpressing cells. Cellular
DNA content data were analyzed as previously mentioned.
Conditional Expression of Skp2 Short Hairpin RNA
To ablate p53 function in LNCaP cells, cells were infected with retro-
virus containing the human papillomavirus type 16 E6 protein and
selected with 500 μg/ml G418 [38,41]. LNCaP, LNCaP + E6, and
DU145 were transduced with lentivirus containing either control or
Skp2-specific short hairpin RNA (shRNA) in the pTRIPZ vector
(nos. 199552 and 12473; Open Biosystems) according to the manu-
facturer’s protocols and selected with 1 μg/ml puromycin to generate
cell lines stably harboring this vector. The expression of multiple Skp2-
targeting shRNAs similarly decreased Skp2 protein expression, and one
construct (no. 199552) was used for the remainder of the experiments.
The expression of control shRNA did not affect Skp2 expression or
proliferation (not shown). Cells were cultured in 2 μg/ml doxycycline
(Sigma) for 7 days and for 7 days with seven additional days ± 2 μg/ml
doxycycline. Cells were lysed for Western blot analysis of protein
expression and were assessed for proliferation by DNA staining.
Statistical Methods
Data were analyzed, SE was calculated, and Student’s t test was per-
formed using Excel (Microsoft Corp, Redmond, WA). Error bars in all
figures represent SE. Analysis of variance (ANOVA) was performed to
determine whether the sizes of control and AZQ-treated xenograft
tumors were significantly different. The Kaplan-Meier estimator was
used to determine whether survival of control or AZQ-treated tumors
was significantly different using a tumor volume of 1200 mm3 as a
surrogate for mortality.
Results
Characterization of Senescence Induction by AZQ in Prostate
Cancer In Vitro and in Xenograft Tumors
The DNA-alkylating drug AZQ (Figure 1A) was recently identified
in a drug screen designed to identify senescence in immortalized cancer
cells by our group [24]. We performed dose-ranging studies and found
that 250 to 500 nM AZQ significantly induced senescence in advanced
prostate cancer cell lines DU145, PC3, and LNCaP cells based on
SA-β-gal staining and morphology (Figure 1B). Detection of apoptosis
by Annexin V and propidium iodide staining 3 days after AZQ expo-
sure revealed cell viability similar to that of controls (Table 1) and a
significant increase in SSC, a measurement of cellular complexity that
is increased in senescent cells [14] (Table 1). Moreover, a significant
percentage of cells accumulated in the G2/M phase after AZQ expo-
sure, suggesting reduced proliferation and growth arrest (Table 1).
These initial results had suggested the possibility that AZQ induces
cellular senescence in these cancer cell lines.
By definition, senescent cells are viable but persistently growth
arrested, even after the addition of mitogens [42]. To demonstrate that
AZQ induces a growth arrest that persists after drug removal, prostate
cancer cell lines were cultured with and without 250 nM AZQ for
3 days. Cell numbers were consistently lower in drug-treated samples,
and this growth inhibition persisted after further culture in drug-free
medium (Figure 1C). Furthermore, after drug removal and 2 weeks
in drug-free medium, AZQ-treated DU145, PC3, and LNCaP cells
remained nonproliferative with senescence-like morphology, although
recovered proliferation of many DU145 cells was apparent (not shown).
These results demonstrate that exposure to AZQ efficiently induces
senescence in a variety of prostate cancer cell lines.
To determine whether AZQ has antiproliferative effects on prostate
tumors in vivo, DU145 xenograft tumors were established in athymic
nude mice and treated with 40% of the maximum tolerated AZQ dose
in mice (10 mg/kg) [25]. Animals with established tumors were treated
for 3 weeks with AZQ (three doses per week) or dimethyl sulfoxide
(DMSO). Tumor growth in AZQ-treated mice was significantly de-
creased and remained largely unchanged until 9 weeks after the initial
treatment, with no effect on animal weight (Figure 2A; ANOVA least
squares, P < .005). Tumors in control mice grew rapidly to 1200 mm3
within 7 weeks, at which point animals were killed. Survival was
significantly prolonged in AZQ-treated tumors (Figure 2B; log-rank,
P < .008). Growth in xenografts injected with only one or three total
doses of AZQ was not significantly affected (not shown).
Samples of harvested tumors were separately frozen in section-
ing medium or were formalin-fixed and paraffin-embedded. Staining
for SA-β-gal activity was increased in AZQ-treated tumors compared
to that in controls (Figure 2C ; Student’s t test, P = .02). AZQ-treated
tumors had decreased proliferation as assessed by Ki-67 quantitation
(Figure 2D; Student’s t test, P = .034). The apoptosis marker cleaved
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caspase 3 was minimally detected and not significantly induced (not
shown). In sum, these data demonstrate that prolonged administra-
tion of low-dose AZQ significantly limited tumor growth, prolonged
survival, and induced characteristics of senescence in a prostate xeno-
graft tumor model in vivo. Given the effectiveness of AZQ to induce
senescence, we evaluated the mechanisms regulating this response.
Induction of the CDKI p27Kip1 and Down-regulation of
Skp2 in TIS
Although CDKI protein expression is central to senescence growth
arrest in fibroblast and epithelial cells, CDKI regulation is frequently
disrupted in cancers [38,42,43]. To identify CDKIs that are upregulated
in TIS, prostate cancer cells were cultured for 3 days in medium contain-
ing 250 nM AZQ, and an additional 3 days in drug-free medium before
protein lysates were harvested. Proteins were then analyzed by immuno-
blot using antibodies identifying the CDKI proteins p21Waf1/Cip1 and
p27Kip1. We found that p27Kip1 expression increases in all three cell
lines after exposure to AZQ and drug-free medium, with a higher basal
expression apparent in LNCaP cells (Figure 3A). The expression of
p21Waf1/Cip1 was not detected in DU145 and PC3 cells, and in LNCaP
cells, the basal expression of p21Waf1/Cip1 was elevated and affected by
AZQ (Figure 3A). The expression of p57Kip2, p16Ink4a, and p15Ink4B
was not detected in any of the three cell lines (data not shown).We then
assessed the expression of p27Kip1 in DU145 xenograft tumors har-
vested 7 days after a single intraperitoneal injection of 4 mg/kg AZQ
(n = 4 each). Both nuclear and cytoplasmic p27Kip1 expressions were
increased in AZQ-treated tumors compared with those in controls
(Figure 3B). Treated tumors also extensively stained positively for
SA-β-gal activity (Figure 2C ). We find that p27Kip1 is the only CDKI
consistently induced in cell lines undergoing senescence growth arrest.
Table 1. Effect of AZQ on Viability, Cellular Granularity (SSC), and Cell Cycle in Prostate
Cancer Cell Lines.
Cell Line Measurement Control +AZQ
DU145 Normalized % viable cells 100 ± 1 75 ± 2*
Normalized SSC 0 ± 5 46 ± 2*
% G1/G0 43.1 ± 0.7 18.0 ± 1.2*
% S 35.9 ± 0.5 16.7 ± 4.7*
% G2/M 21.0 ± 0.6 65.2 ± 3.8*
PC3 Normalized % viable cells 100 ± 1 96 ± 3
Normalized SSC 0 ± 5 76 ± 5*
% G1/G0 44.8 ± 2.0 19.1 ± 1.1*
% S 33.0 ± 3.1 15.9 ± 1.1*
% G2/M 22.2 ± 1.9 65.0 ± 1.9*
LNCaP Normalized % viable cells 100 ± 7 84 ± 8
Normalized SSC 0 ± 6 131 ± 7*
% G1/G0 69.0 ± 0.9 36.7 ± 0.9*
% S 17.3 ± 2.1 21.2 ± 1.0
% G2/M 13.6 ± 1.7 42.1 ± 2.8*
All Data Normalized % viable cells 100 ± 1 85 ± 3*
Normalized SSC 0 ± 3 85 ± 13*
% G1/G0 52.3 ± 8.4 24.6 ± 6.1
†
% S 28.7 ± 5.8 17.9 ± 1.7
% G2/M 19.0 ± 2.7 57.5 ± 1.7*
*P < .01, two-tailed equal variance Student’s t test.
†P < .05, two-tailed equal variance Student’s t test.
Figure 1. AZQ induces senescence in prostate cancer cells in vitro. (A) Structure and molecular weight of AZQ (NSC 182986). (B) Morphol-
ogy and SA-β-gal staining of control DU145, PC3, and LNCaP cells and after 3 days cultured with medium containing 250 nM AZQ and with
additional 3 days of recovery in drug-free medium. Scale bar, 20 μm. (C) AZQ inhibits prostate cancer cell growth. Prostate cancer cells were
cultured in medium + DMSO (Control) or in medium + 250 nM AZQ for 3 days and then cultured for three additional days in drug-free
medium to day 6 (+ AZQ). Viable cell number was measured as described in Materials and Methods. Student’s t test, *P < .02, **P < .01.
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We next investigated whether expression of the p27Kip1-regulator
Skp2 is altered in AZQ-induced senescence. Initial experiments mea-
suring mRNA expression showed no increase in p27Kip1 transcription
in DU145 or PC3 cells after AZQ (not shown). In contrast, in pro-
tein lysates of cells treated with 250 nM AZQ and allowed to recover
in drug-free medium, the expression of Skp2 decreased compared to that
in proliferating cells (Figure 4A).We addressedwhether changes in Skp2
and p27Kip1 expression were AZQ-specific or occurred in senescence in-
duced by other drugs. Prostate cancer cells were cultured with AZQ and
known senescence-inducing doses of the DNA-damaging anthracycline
doxorubicin (DOX) or the DNA methyltransferase inhibitor 5-AZA
[3,16]. Protein lysates were harvested at multiple time points after drug
exposure and analyzed by immunoblot analysis. Skp2 expression was
reduced at later time points after senescence-inducing drug contact
consistent with induction of the senescent phenotype (Figure 4B).
However, the increased expression of p27Kip1 appeared earlier than
decreased Skp2 in these time-course experiments, a point that will be
experimentally addressed in later paragraphs. In summary, these data
demonstrate that changes in p27Kip1 and Skp2 expression constitute
a consistent molecular change in prostate cancer cell lines exposed to
senescence-inducing doses of various drugs.
Skp2 activity is regulated by nuclear/cytoplasmic localization in
addition to expression [33]. We used immunofluorescence to deter-
mine whether changes in Skp2 localization that occur in TIS would
explain the kinetics of p27Kip1 and Skp2 expression (Figure 4B). In
control cells, minimal p27Kip1 is detected, whereas Skp2 expression is
primarily localized in the nucleus of PC3 cells (Figure 4C). Early after
exposure to AZQ (days 2 and 3), increased p27Kip1 is detected and
Skp2 expression is translocated from the nucleus to the cytoplasm.
With development of the full senescent phenotype (observed in cells
6 days after initial drug exposure), nuclear expression of p27Kip1 is in-
creased and Skp2 expression decreased. These data indicate that Skp2
translocation from the nucleus to the cytoplasm is an early event that
regulates p27Kip1 accumulation during TIS.
Skp2 Regulates Growth Arrest in TIS
Skp2 regulates the expression of p27Kip1 in numerous cell types,
including prostate cells [27]. To determine the role Skp2 plays in
Figure 2. AZQ induces senescence growth arrest in DU145 xenograft tumors in vivo. After 3 weeks of growth to measurable size
(week 0), tumor-bearing mice were given intraperitoneal injections of control DMSO in PBS or 4 mg of AZQ/kg body weight three times
a week for 3 weeks (n = 4 for each). (A) Change in size of established DU145 xenograft tumors. Note the persistence of tumor growth
inhibition after 3 weeks (*ANOVA, P < .005). (B) Kaplan-Meier analysis of time for Control or +AZQ tumors to reach study end point of
1200-mm3 tumor volume (log rank, P< .008). (C) SA-β-gal staining is induced in AZQ-treated tumors compared with controls. These data
represent the average number of positive staining cells per 400× high-power field in five views per tumor (n = 4 tumors each). Student’s
t test, P = .009. (D) Decreased expression of the proliferation marker Ki-67 in +AZQ tumors versus Control measured as in C. Student’s
t test, P = .034.
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TIS, we first tested whether Skp2 overexpression could rescue the
senescence-inducing effect of AZQ. Cells were coelectroporated with
a plasmid expression vector containing the cDNA for Skp2 or control
LacZ and a GFP expression vector to specifically monitor electro-
porated cells [40]. In preliminary experiments, transient overexpression
of Skp2 persists 3 days after electroporation, after which expression de-
creases markedly (not shown). Therefore, cells were exposed to 250 nM
AZQ 24 hours after electroporation and were assessed 2 days later.
Cells were harvested and analyzed for protein expression by immuno-
blot analysis and for proliferation by flow cytometry (Figure 5A). In
LacZ-expressing cells, AZQ exposure increased p27Kip1 expression
and decreased the fraction of cells in the S phase, consistent with cellular
senescence. In Skp2-overexpressing cells, p27Kip1 expression did not in-
crease after AZQ exposure, and S phase was increased (Figure 5B).
These results demonstrate that forced overexpression of Skp2 interrupts
the response to AZQ indicating that decreased Skp2 is necessary for
TIS growth arrest.
Previous studies have shown that the increased expression of p27Kip1
is associated with senescence in human prostatic intraepithelial neo-
plasia (PIN) and in cell lines [7,26]. We addressed whether reduced
expression of Skp2 is sufficient to induce senescence in cancer cells.
Stable prostate cancer cell lines derived from LNCaP, DU145, and
LNCaP + E6 cells (expressing the p53-targeting human papillomavirus
type 16 E6 protein) were developed to express Skp2 shRNA in the
presence of 2 μg/ml doxycycline. Basal expression of Skp2 was highest
in LNCaP cells and diminished in DU145 and LNCaP + E6.
After 7 days of exposure to doxycycline, all cell lines reduced
expression of Skp2 (Figure 5C , plus symbols “+”). LNCaP showed
a marked increase in p27Kip1 expression, whereas this relative increase
was not as large in cell lines with lower basal Skp2 (Figure 5C ). Skp2
down-regulation resulted in reduced proliferation in LNCaP cells. The
growth inhibition of Skp2 down-regulation persisted in LNCaP-
derived cells even 7 days after doxycycline was removed from the
growth medium. No significant effect on proliferation was seen in
DU145- and LNCaP + E6–derived cells (both p53 deficient). Skp2
knockdown did not induce other characteristics of senescence in any
cell line, including SA-β-gal activity, expression of the SA-β-gal–related
protein Glb1, or increased cellular granularity/SSC (not shown). Our
results demonstrate that while Skp2 reduction is necessary to mediate
TIS and p27Kip1 expression, decreased Skp2 activity itself is not suffi-
cient to induce the full senescence phenotype in cancer cells. These
results also suggest that cell lines expressing lower basal levels of
Skp2 are less responsive to Skp2 down-regulation.
Discussion
In senescence, many studies have addressed the induction and mainte-
nance of senescence in nontransformed cells, either through oncogene-
induced senescence or replicative senescence. These tumor suppression
processes are frequently disrupted or bypassed in cancer cells. While
the idea of TIS as an alternative to cytotoxic treatment strategies was first
proposed almost a decade ago [14], a number of recent studies illustrate
a quickly growing interest in this topic [13,20,23,24,33,44–46]. How-
ever, little is known regarding the regulation of the senescence response
in cancer cells.
One obstacle facing senescence research is a lack of specific senescence-
inducing compounds. In the current study, we characterized the novel
Figure 3. Increased expression of CDKI p27Kip1 in senescent prostate cancer cell lines in vitro and DU145 xenografts in vivo after AZQ
treatment. (A) DU145, PC3, and LNCaP cells were cultured for 3 days in medium containing 250 nM AZQ (+AZQ 3 Days) or were exposed
to AZQ and cultured an additional 3 days in drug-free medium (Removal + 3 Days), protein lysates were harvested. Lysates of nonconfluent
proliferating cells were used as controls. Lysates of normal human prostate epithelial cells after one and five passages were included.
Expression of α-tubulin was included as a loading control. Band intensities are normalized to α-tubulin and expressed relative to controls.
(B) Immunofluorescencemicroscopy of p27Kip1 expression (red) in Control or +AZQ tumors harvested 7 days after a single injection of 4 mg
of AZQ per kilogram body weight. DNA is stained using Hoechst 33342 (blue). Scale bar, 20 μm.
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in vitro and in vivo senescence-inducing activity of AZQ, a compound
recently identified in a high-throughput senescence screen of small
molecules [24]. Although this compound had been previously devel-
oped to treat neural and hematological malignancies, limited testing
was performed in patients with solid tumors [25]. Moreover, this com-
pound was developed before any awareness of TIS as a tumor response.
Our results show that the exposure of a panel of prostate cancer cell
lines to 250-nM concentrations of AZQ effectively induces senescence
in vitro. We also demonstrate that low-dose AZQ administered over
extended periods induces senescence with limited apoptosis in prostate
tumor xenografts in vivo. Tumor growth is significantly inhibited and
survival is prolonged. These findings provide initial proof-of-principle
for the potential of TIS in cancer treatment and prompt the investigation
of other quinone and diaziquone analogs for TIS activity in cancer.
Figure 4. Translocation and decreased expression of Skp2 in senescent prostate cancer cells after treatment with multiple senescence-
inducing drugs. Band intensities are normalized to α-tubulin and expressed in relative units. (A) Immunoblot analysis of p27Kip1 and its
relationship to Skp2 in proliferating DU145 and PC3 cells induced to senescence by 250 nM AZQ. Cells were exposed to DMSO (−) or
AZQ (+) for 3 days with 3 days of recovery in drug-free medium before harvesting. (B) Time course experiments in PC3 using multiple
senescence-inducing agents. Immunoblot analysis of p27Kip1 and Skp2 expression in untreated PC3 cells (Control) harvested at multiple
time points after adding the senescence-inducing drugs AZQ, doxorubicin (DOX), or 5-AZA. Treated PC3 cells were harvested after 2 and
3 days of drug exposure and after 3 days of incubation with drug followed by 3 days in drug-free medium (Removal + 3 Days). p27Kip1
expression is induced before Skp2 down-regulation with all drugs analyzed. (C) Immunofluorescence microscopy of p27Kip1 (red) and
Skp2 (green) over time during TIS in PC3 cells. Cells were fixed and stained after incubation with AZQ as above. Nuclei were stained with
Hoechst 33342 (blue). Scale bar, 20 μm.
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Furthermore, AZQ provides a model compound for the investigation
of mechanisms that regulate TIS.
In seeking to define pathways involved in TIS, we screened a panel of
CDKIs and found that p27Kip1 expression increases during TIS in the
prostate cancer cell lines investigated. p27Kip1 has tumor-suppressor
functions [47], and its targeted disruption leads to prostatic hyperplasia
in mice [48]. In human epithelial cancers, including prostate, p27Kip1
is commonly downregulated, and this loss of expression correlates
with outcome [49]. Disruption through deletion or mutation rarely
occurs in human tumors [50,51]. We found that, in the p53-defi-
cient cell lines DU145 and PC3, p27Kip1 is the only CDKI that is
induced. Increased p27Kip1 expression is a consistent feature of TIS
in cancer cells induced through multiple agents and provides a po-
tential marker of this process. Because p16Ink4a plays a primary role
in the replicative senescence of nontransformed primary prostate
epithelia cells [38,41], the expression of p27Kip1 may represent a
Figure 5. Skp2 is necessary, but not sufficient for TIS. Band intensities are normalized to α-tubulin and expressed in relative units. (A) Over-
expression of Skp2 in PC3 cells. PC3 cells were incubated overnight after coelectroporation of GFP with either LacZ or Skp2 expression
vectors. Cells were harvested 3 days after electroporation. (B) Overexpression of Skp2 disrupts the senescence response to AZQ. PC3 cells
were electroporated, allowed to recover overnight, incubated in drug-free medium (−) or medium + 250 nM AZQ for 2 days, and analyzed
for both protein expression and DNA content/cell cycle phase. The overexpression of Skp2 inhibits p27 induction and prevents the decrease
in S-phase seen after AZQ treatment. Similar results were demonstrated in DU145 (not shown). (C) Persistent down-regulation of Skp2
expression inhibits proliferation in LNCaP but not DU145 and LNCaP + E6 cells. Skp2-specific shRNAs were expressed in LNCaP,
DU145 (DU), and LNCaP + E6 cells (LN + E6). Cells were cultured for 7 days in drug-free medium (−) or with 2 μg/ml doxycycline (DOXY)
(+), for 14 days with 2 μg/ml doxycycline (++), or for 7 days with 2 μg/ml doxycycline followed by 7 days in doxycycline-free medium (+−).
Parallel samples were analyzed for protein expression and DNA content/cell cycle phase. Skp2 down-regulation inhibits proliferation in
LNCaP cells but not DU145 and LNCaP + E6 cells. Student’s t test, *P < .05, **P < .01.
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backup mechanism for regulating cell cycle arrest and TIS in trans-
formed cancer cells.
We found that the regulation of p27Kip1 in TIS occurs post-
translationally and is dependent on Skp2. Recently, Skp2 loss was
found to restrict tumorigenesis in Skp2−/− Pten+/− compound mutants
[46]. Our results demonstrate for the first time that Skp2 down-
regulation is necessary for TIS. We found that Skp2 expression
decreases after TIS induced through a variety of agents (Figure 4B).
TIS can be stimulated through multiple mechanisms including
DNA damage and demethylation [13], induced by doxorubicin and
5-AZA, respectively. Decreased Skp2 is necessary for TIS induced
by AZQ because the overexpression of Skp2 blocks growth inhibition
after drug exposure in cell lines (Figure 5). Our data suggest that Skp2,
a gene frequently upregulated in prostate and other cancers [28], has
a major role in the senescence response in cancer cells. Furthermore,
up-regulation of Skp2 may be involved in the resistance of senescence
induction in cancer cells during treatment.
We also report the novel observation that decreased expression of
Skp2 alone does not induce the full senescent phenotype that is
observed with AZQ and other agents (Figure 5C ). The regulation of
replicative senescence and oncogene-induced senescence in nontumor
cells has been the focus of multiple investigations [42]. However, the
regulation of senescence in cancer cells that lack the function of many
tumor suppressors is not well defined. The extended down-regulation
of Skp2 expression using stable shRNAs was not sufficient to induce
senescence in any cell line. Inhibition of proliferation was more sig-
nificant in LNCaP that expressed higher levels of Skp2 and markedly
induced p27Kip1. This lack of effect in other lines may be related to the
lower basal expression of Skp2.
The failure of Skp2 to induce senescence suggests that other
molecular pathways, possibly upstream of Skp2, are required for the
full development of the senescent phenotype by TIS. For instance,
the targeting of FOXM1, a transcription factor that regulates expres-
sion of Skp2 and other genes, induces senescence in gastric cancer
cells [34]. Another potential upstream mediator of TIS is myc, whose
oncogenic activity induces senescence in nontransformed cells and
regulates p27Kip1 expression through Skp2 [52,53]. Activities of these
transcription factors in addition to Skp2 regulation may prove to be
critical for complete senescence induction. In addition, other proteins
are also reported to interact with p27Kip1 to regulate its stability, in-
cluding ubiquitin ligases SIAH1/SIP and KPC [54,55]. Recently,
MLN4924, a compound that disrupts the activity of multiple ubiquitin
ligases in addition to Skp2, was found to induce senescence in PC3
[46]. TIS induction with AZQ, doxorubicin, and 5-AZA down-
regulate Skp2 but clearly have the capacity to induce other signals
including damage response signal transduction to generate a full
senescence response in cancer. Skp2 represents one component of this
response, and future study is required to identify other common
pathways regulating TIS.
In summary, we conclude that AZQ induces senescence in prostate
cancer cells in vitro and in xenograft tumors in vivo. The drug AZQ
provides a benchmark by which future senescence-inducing com-
pounds may be compared both in vitro and in tumor models. This
drug also presents a tool with which the mechanisms regulating
drug-induced senescence and the consequences of this response in
tumors may be addressed. Decreased Skp2 and increased p27Kip1 are
required for TIS induced by multiple drugs. Skp2 and p27Kip1 need
further investigation as putative markers of the senescence response
in treated and untreated tumor tissues. Furthermore, our results suggest
that TIS in tumors might be more efficiently achieved by broad stress-
inducing agents or by targeting regulators of upstream pathways.
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